Radiopharmaceuticals and Immunotherapeutics

for Novel Targets from our



ImmunoPET and Immunotherapy for Fibrosis and Cancer

“Nanobody” is a registered trademark of Ablynx NV, Sanofi


Cortalix is a clinical-stage biopharmaceuticals company developing PET-imaging diagnostics, targeted radiotherapeutics and immunotherapeutics for novel targets based on its proprietary nanobody* (single-domain antibody) platforms. 

Internal programs

Cortalix has a growing number of Internal Programs of selected nanobody-based radiopharmaceuticals in the field of fibrosis and fibrotic cancers, which we are developing ourselves in the clinic or making available for co-development or licensing.

Partner programs

Cortalix collaborates with other pharmaceutical companies and academic research groups in Partner Programs to screen and select new suitable nanobody candidates for novel targets. We develop these nanobodies not only into fully-fledged radiopharmaceuticals, but also for other (immuno)therapeutic and diagnostic applications.


Finally, we use our libraries to carry out nanobody selection and development as fee-for-service for several companies and research groups for very different applications, including targeted therapy, immunotherapy, but also for research tools and bioanalytical applications such as immunohistochemistry, fluorescence imaging, tailored affinity columns, and ELISA development and validation.

Latest open positions

VP Business Development

Job description: VP Business Development. Type: 20% – 50%. Location: Innolab Agrifood, Groningen, The Netherlands. Date: Immediate. About the role At Cortalix, The VP Business Development is responsible for managing and developing Cortalix’s business development...

read more

Latest news and events


If you would like to know more about our organization, or would like to know how we can support your projects, please complete the contact form. We will contact you shortly.